IDEXX Laboratories, Inc. (NASDAQ:IDXX) CEO Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $153.61, for a total value of $2,764,980.00. Following the completion of the transaction, the chief executive officer now owns 1,064,573 shares in the company, valued at $163,529,058.53. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of IDEXX Laboratories, Inc. (IDXX) traded up $2.68 on Thursday, reaching $154.08. The company’s stock had a trading volume of 746,292 shares, compared to its average volume of 713,709. IDEXX Laboratories, Inc. has a 12 month low of $112.67 and a 12 month high of $173.01. The company has a current ratio of 0.95, a quick ratio of 0.77 and a debt-to-equity ratio of -12.48. The firm has a market cap of $13,440.00, a PE ratio of 50.35, a P/E/G ratio of 2.26 and a beta of 0.46.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.05. The firm had revenue of $492.00 million for the quarter, compared to analyst estimates of $492.94 million. During the same period in the prior year, the firm posted $0.62 EPS. The business’s revenue was up 9.7% compared to the same quarter last year. equities research analysts predict that IDEXX Laboratories, Inc. will post 3.24 EPS for the current fiscal year.

WARNING: “Jonathan W. Ayers Sells 18,000 Shares of IDEXX Laboratories, Inc. (IDXX) Stock” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/11/16/jonathan-w-ayers-sells-18000-shares-of-idexx-laboratories-inc-idxx-stock.html.

Institutional investors and hedge funds have recently modified their holdings of the business. D.A. Davidson & CO. lifted its position in IDEXX Laboratories by 160.4% during the 2nd quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock worth $100,000 after acquiring an additional 385 shares during the period. Sun Life Financial INC lifted its position in IDEXX Laboratories by 9,085.7% during the 2nd quarter. Sun Life Financial INC now owns 643 shares of the company’s stock worth $104,000 after acquiring an additional 636 shares during the period. BB&T Investment Services Inc. acquired a new stake in IDEXX Laboratories during the 2nd quarter worth about $104,000. Capital Advisors Ltd. LLC acquired a new stake in IDEXX Laboratories during the 2nd quarter worth about $128,000. Finally, Zions Bancorporation acquired a new stake in IDEXX Laboratories during the 3rd quarter worth about $162,000. 88.03% of the stock is owned by institutional investors.

IDXX has been the topic of a number of analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a report on Friday, October 6th. BidaskClub cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective for the company in a research report on Tuesday, October 24th. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research report on Monday, August 21st. Finally, Bank of America Corporation raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective for the company in a research report on Wednesday, August 23rd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $173.67.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.